

PHARMACOLOGY
BIOCHEMISTRY
AND
BEHAVIOR

VOLUME 44, 1993
SUBJECT AND AUTHOR INDEX



Pergamon Press
New York • Oxford • Seoul • Tokyo

PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

Editor-in-Chief

MATTHEW J. WAYNER

Division of Life Sciences, The University of Texas at San Antonio, San Antonio, TX 78285

Editorial Advisory Board

- | | |
|--|---|
| ROBERT L. BALSTER, Virginia Commonwealth University,
Richmond, VA | GEORGE F. KOOB, Research Institute of Scripps Clinic,
La Jolla, CA |
| BERNARD BEER, Medical Research Division of American
Cyanamid, Pearl River, NY | CONAN KORNETSKY, Boston University Medical Center,
Boston, MA |
| ROBERT J. BLANCHARD, University of Hawaii, Honolulu, HI | J. DAVID LEANDER, Lilly Research Laboratories,
Indianapolis, IN |
| ALLAN C. COLLINS, University of Colorado at Boulder,
Boulder, CO | ALLEN S. LEVINE, Veterans Administration Medical Center,
Minneapolis, MN |
| DONALD V. COSCINA, Clark Institute of Psychiatry, Toronto,
Ontario, Canada | WILLIAM J. McBRIDE, Indiana University School of Medicine,
Indianapolis, IN |
| JACQUELINE N. CRAWLEY, Clinical Neuroscience Branch,
NIMH, Bethesda, MD | DONALD E. McMILLAN, University of Arkansas for Medical
Sciences, Little Rock, AR |
| ADRIAN J. DUNN, Louisiana State University, Shreveport, LA | H. MATTHIES, Medical Academy of Magdeburg, Magdeburg,
Germany |
| BURR EICHELMAN, Temple University, Philadelphia, PA | JACK H. MENDELSON, McLean Hospital, Belmont, MA |
| JOHN L. FALK, Rutgers University, New Brunswick, NJ | FATHY S. MESSIHA, University of North Dakota,
Grand Forks, ND |
| SANDRA E. FILE, Guys Hospital Medical School, London,
England | LAURENCE R. MEYERSON, Marion Merrell Dow, Inc.,
Kansas City, MO |
| WILLIAM J. FREED, National Institute of Mental Health,
Washington, DC | LAWRENCE D. MIDDAGH, Medical University of South
Carolina, Charleston, SC |
| RICHARD A. GLENNON, Virginia Commonwealth University,
Richmond, VA | ROBERT D. MYERS, East Carolina University School of Medicine,
Greenville, NC |
| A. J. GOUDIE, University of Liverpool, Liverpool, England | KIM T. NG, LaTrobe University, Bundoora, Victoria, Australia |
| F. G. GRAEFF, Universidade de São Paulo, São Paulo, Brazil | JAAK PANKSEPP, Bowling Green State University,
Bowling Green, OH |
| M. R. C. GREENWOOD, University of California at Davis,
Davis, CA | JOHN A. ROSECRANS, Medical College of Virginia,
Richmond, VA |
| ROLAND R. GRIFFITHS, The Johns Hopkins University School of
Medicine, Baltimore, MD | HERMAN H. SAMSON, Bowman Grey School of Medicine,
Winston-Salem, NC |
| J. HANO, Polish Academy of Sciences, Krakow, Poland | PAUL R. SANBERG, University of South Florida, Tampa, FL |
| STEPHEN G. HOLTZMAN, Emory University School of Medicine,
Atlanta, GA | DAVID S. SEGAL, University of California School of Medicine,
La Jolla, CA |
| AKIRA HORITA, University of Washington, Seattle, WA | PHIL J. SKOLNICK, National Institutes of Health, Bethesda, MD |
| WALTER A. HUNT, NIAAA, Rockville, MD | DEREK VAN DER KOOT, University of Toronto, Toronto,
Ontario, Canada |
| JOSEPH P. HUSTON, University of Dusseldorf, Dusseldorf,
Germany | JEANNE M. WEHNER, University of Colorado at Boulder,
Boulder, CO |
| CHRIS E. JOHANSON, Addiction Research Center,
Baltimore, MD | J. C. WINTER, State University of New York School of Medicine,
Buffalo, NY |
| HAROLD KALANT, University of Toronto, Toronto, Ontario,
Canada | ALICE M. YOUNG, Wayne State University, Detroit, MI |
| G. JEAN KANT, Walter Reed Army Institute of Research,
Washington, DC | IAN S. ZAGON, M. S. Hershey Medical Center, Hershey, PA |
| KATHLEEN M. KANTAK, Boston University, Boston, MA | |
| ABBA J. KASTIN, Veterans Administration Medical Center, New
Orleans, LA | |
-

PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

Editorial Offices:

Matthew J. Wayner

Division of Life Sciences, The University of Texas at San Antonio, San Antonio, TX 78285

Production Editor:

Sara Beth Morrone

Pergamon Press, Tarrytown, NY 10591-5153

Publishing, Subscription, and Advertising Offices:

Pergamon Press Inc., 660 White Plains Road, Tarrytown, NY 10591-5153, USA, INTERNET
"PPI@PERGAMON.COM" and Pergamon Press Ltd., Headington Hill Hall, Oxford OX3 0BW, England

Published Monthly

Annual institutional subscription rate (1993): £785 (US\$1256)

Sterling prices are definitive. US dollar prices are quoted for convenience only and are subject to exchange rate fluctuation. Prices include postage and insurance and are subject to change without notice.

SUBJECT INDEX

- AA and ANA rats, 127
 Acatalasemic mice, 547
 Acetaldehyde, 547
 Acetylcholine, 425, 615
 Acetylcholinesterase, 339
 Acetylcholinesterase inhibition, 689
 Acquisition, 419
 ACTH(4-9) analogue ORG2766, 565
 ACTH/MSH(4-9) analog, 447
 Activity, 221
 Activity assessment, 167
 Adaptation, 375
 Addiction, 735
 Adenosine analogs, 113
 Adenosine receptors, 199
 Adrenocorticotrophic hormone, 533
 Aerosol, 891
 Age, 805
 Aggression, 821
 Aggressive behavior, 237, 519
 Aging, 17, 87, 475, 577, 703
 Akathisia, 181
 Alcohol, 133, 307, 403
 Alcohol-induced hypothermia, 307
 Alcoholism, 951
 Alcohol preference, 127
 α_2 -adrenergic, 777
 α_1 -adrenoceptors, 519
 α_2 -adrenoceptor(s), 1, 475, 519
 α -melanocyte-stimulating hormone, 533
 α_1 -receptor, 381
 α_2 -receptor, 381
 α -site, 349
 Alprenolol, 851
 Alzheimer's disease, 37, 491
 Ambulation, 627
 Amino acids, 87
 Aminoxyacetic acid, 63
 Amperozide, 27
 Amphetamine, 27, 77, 199, 241, 245, 287, 397, 481, 735
 Amygdala, 425
 Amylin, 577
 Anabolic steroids, 959
 Analgesia, 1, 45, 153
 Anesthesia, 145
 Anesthetized conspecific, 313
 Angiotensin, 985
 Anhedonia, 181
 Animal model(s), 463, 491
 Anorexia, 77, 577, 595
 Anterior hypothalamus, 533
 Anterior pituitary gland, 755
 Anterograde amnesia, 145
 Anticholinergic compounds, 615
 Anticholinesterase, 689
 Anticonvulsant mechanism, 709
 Anticonvulsants, 615
 Antidepressants, 519
 Antiemetic, 745
 Antinociception, 433, 643
 Antiparkinsonian drugs, 615
 Anxiety, 127, 153, 241, 433, 471, 509, 633
 Anxiogenic stimuli, 463
 Apomorphine, 601, 741
 Arousal, 393
 AT-1 and AT-2 receptors, 623
 Atropine, 287
 Atypical neuroleptic, 181
 Autoradiography, 877
 Autoreceptor, 601
 Autoshaping, 877, 959
 Aversion, 119
 Avoidance, 233
 Avoidance learning, 451
 Behavior, 661, 665
 Behavioral observation, 167
 Benzodiazepine receptor, 783
 Benzodiazepine(s), 433, 471, 633
 β -adrenoceptors, 869
 β -blockers, 611
 β -carboline(s), 633, 951
 β -casomorphins, 227
 β -CCE, 633
 β -funaltrexamine, 497
 Bicuculline methiodide, 943
 Bimodal antinociception, 365
 Blood glucose, 217
 Blood pressure, 573, 623
 BMY 14802, 349
 Body temperature, 717
 Body weight, 959
 Bombesin scratch test, 45
 Bradycardia, 1
 Brain, 63
 Brain energy metabolism, 491
 Brain injury, 297
 Brain regions, 63
 Brain-stimulation reward, 425
 Buspirone, 633
 Butorphanol, 1
 Butorphanol dependence, 497
 Caerulein, 509
 Caffeine, 199, 287, 393, 457
 Calcium channel(s), 17, 99, 661
 Calcium channel antagonist, 827
 Cannabinoid, 745
 Carbon dioxide, 633
 Carbon monoxide, 387
 Cardiac pacemaker, 869
 Catalase, 547
 Catecholamines, 71, 615, 791, 869
 Cathinone, 657
 Caudate putamen, 87, 157
 CCK receptors, 509
 CCK-4, 509
 Cellular/dispositional tolerance, 717
 Cerebellum, 297
 Cerebral cortex, 237, 267
 CGRP, 577
 CGS 10746B, 661
 Chlordiazepoxide, 717
 Cholecystokinin, 249
 Choline, 587
 Choline acetyltransferase, 491
 Cholinergic receptors, 199
 Cholinergic regulation, 913
 Cholinergic system, 587
 Cholinesterase inhibitor(s), 615, 769
 Chronic, 51, 375
 Chronic administration, 181, 587
 Chronic treatment, 827
 Cigarette, 387
 Cigarette smoking, 891
 Circular platform, 877
 Classic conditioning, 965
 Clonic convulsion, 727
 Clonidine, 777, 821
 Clorgyline, 321
 Clozapine, 181, 741
 Cocaine reinforcement, 471
 Cocaine withdrawal, 253
 Cocaine, 27, 161, 191, 199, 221, 281, 365, 481, 651, 661, 907
 Coffee consumption, 573
 Cold and immobilization stress, 339
 COLD mice, 501
 Conceptual and acoustic acquisition, 393
 Conditioned fear stress, 371
 Conditioned place preference, 191, 245
 Conditioned response, 275
 Conditioned taste aversion(s), 249, 263, 985
 Consolidation, 419
 Continuous cocaine, 971
 Continuous recognition memory, 419
 Convulsions, 113, 615
 Corpus striatum, 751
 Cortex, 157
 Corticotropin-releasing factor, 375, 755
 Cortisol, 527
 Cotinine, 387
 CRF, 925
 CRF receptors, 755
 Cross-tolerance, 981
 CTL response, 275
 Cyclohexyladenosine, 113

- d*-amphetamine, 167, 751
 D₁ and D₂ receptors, 167
 Defense, 673
 Defensive behavior, 433
 Defensive withdrawal, 925
 Delayed nonmatching, 411
 Deprenyl, 321
 Devazepide, 509
 Development, 763, 975
 Developmental, 403
 Dextrofenfluramine, 989
 Diabetes, 837
 Diabetes mellitus, 577
 Diazepam, 267, 287, 313, 463
 Diet selection, 919
 Discriminative stimulus effects, 907
 Disinhibition, 181
 Dissociative anesthesia, 1
 Distribution, 9
 Dog, 181
 Dopamine, 87, 227, 425, 487, 565, 601, 605, 661, 791, 843
 Dopamine antagonists, 167
 Dopamine D₁ antagonist, 429
 Dopamine D₂ receptor, 865
 Dopamine metabolism, 615
 Dopamine receptors, 821, 907
 Dopaminergic system, 365
 Dorsal immobility response, 157, 329
 Dorsal striatum, 329
 DPAG, 119
 D₁ receptor, 843
 D₂ receptor(s), 487, 627, 843
 D₃ receptor, 487
 Drinking, 77
 DRRD, 181
 Drug, 745
 Drug abuse, 959
 Drug antagonists, 791
 Drug discrimination, 349, 481, 661, 769, 851
 Drug discrimination learning, 249
 Drug reinforcement, 191
 DuP996, 37
 Dynorphine A 1-8, 329
 Dynorphine A 1-17, 329
 Dynorphine A 2-8, 329
 Dynorphine A 2-17, 329

 8-OH-DPAT, 357, 777, 851
 Elevated plus-maze, 119, 127, 241, 463
 Elimination rates, 307
 Emotional reactivity, 783
 Environment, 141
 Epilepsy, 113
 Epileptogenesis, 425
 Ergometry, 527
 Escapable and inescapable foot-shock, 869
 Escape, 119, 233, 673
 Ethanol, 241, 263, 313, 403, 501, 547, 791, 931, 943, 981
 Ethanol dependence, 943
 Ethanol oxidation, 547
 Ethosuximide, 975
 Excitatory amino acid receptor, 727
 Excitatory amino acids, 539
 Exploration, 783
 Extinction, 959
 Extrapyrmidal symptoms, 181

 Fasting, 71
 Fear, 433

 Feeding, 51, 77, 595, 605, 777, 919, 989
 Feeding behavior, 217
 Female, 281
 Fenfluramine, 595, 931
 Fetal Alcohol Syndrome, 307
 FG7142, 333
 Fischer 344 rat, 919
 5-aminovaleic acid, 107
 5-HIAA, 371
 5-HT, 457, 555
 5-HT₁, 161
 5-HT₂, 161
 5-HT₃, 161
 5-HT₃ antagonist, 387
 5-HTP, 457
 5-HT_{1A} receptor(s), 253, 357
 5-HT₂ receptors, 457
 5-hydroxytryptamine, 107
 5-hydroxytryptophan, 357
 5,7-DHT, 457
 Fixed-ratio discrimination, 815
 Flumazenil, 581, 857
 Flumazenil-precipitated abstinence, 857
 Flunarizine, 99
 Fluoxetine, 931
 Flurothyl, 63
 Folic acid, 703
 Folinic acid, 703
 Food consumption, 107
 Food hoarding, 565
 Food intake, 577, 919
 Foot-shock stress, 371
 Forced swim, 925
 Freezing behavior, 371
 Frontal cortex, 565

 GABA, 63, 333, 943
 GABA_A, 267
 GABAergic receptors, 133
 GABA_A receptors, 237
 GABA turnover, 63
 γ-rays, 809
 Gender differences, 233
 Generalization, 249
 Genetics, 133
 Genotype, 821
 Gepirone, 313
 Gerbil, 17
 Globus pallidus, 157
 Glutamate, 245, 539
 GM1 ganglioside, 565
 Grooming, 627
 Guanidinoethanesulphonic acid, 107
 Guinea pig, 925

 Habituation, 463
 Hallucinogens, 865
 Haloperidol, 157, 181, 233, 735, 741
 Haloperidol-sensitive, 349
 Harmane, 951
 Head-twitch response, 457
 Heart rate, 527
 Height, 463
 Heroin, 191, 735
 HI-6, 689
 [³H]MK-801 binding, 683
 HOT mice, 501
 Hot plate, 9
 Housing conditions, 141
 [³H]SCH 23390 binding, 683
 [³H]Spiroperidol binding, 683
 Human(s), 387, 527

 Hyperactivity, 397
 Hyperbaric oxygen, 357
 Hypercapnia, 1
 Hyperlocomotion, 227
 Hyperphagia, 77
 Hyperthermia, 533
 Hypotension, 1
 Hypothalamic-pituitary-adrenal axis, 665
 Hypothalamus, 837
 Hypothermia, 357
 Hypoxemia, 1

 Ibotenic acid, 877
 ICI-169,369, 797
 ICI-170,809, 797
 Impulsivity, 393
 Inbred rats, 919
 Infant learning, 403
 Infantile stimulation, 783
 Inhibitory avoidance, 447
 Intensification of morphine physical dependence, 939
 Interaction, 777
 Interictal activity, 709
 Intermittent cocaine, 971
 Intrathecal, 9
 Intrathecal injection, 439
 Isolation, 519, 925
 Isoproterenol, 623
 Israpidine, 661

 Juvenile rats, 763

 Kainate-type glutamate receptor, 727
 κ-opioids, 77
 Ketamine, 539
 Ketanserin, 161
 Kindling, 113

 Latent inhibition, 751
 Lateral hypothalamus, 217
 L-β-methylamino-alanine, 727
 Lead, 221
 Learned tolerance, 717
 Learning, 287, 433, 877
 Lesion, 877
 Lethality, 343
 Lever press, 959
 Lewis rat, 919
 L-5-hydroxytryptophan, 989
 L-glutamic acid diethyl ester, 539
 LHSS, 901
 Linear locomotion, 429
 Linopirdine, 37
 Locomotion, 791, 865
 Locomotor activity, 27, 107, 127, 167, 199, 547, 959
 Locus coeruleus, 297
 Long-lasting upregulation by morphine of NMDA receptors, 939
 Long-lasting upregulation by naloxone of NMDA receptors, 939
 Lorazepam, 633
 Losartan, 623
 L-tryptophan, 651
 Luteinizing hormone, 837
 LY 171555-induced hypermotility, 683

 MAO-A, 321
 MAO-B, 321
 Marijuana, 745
 MDA, 965

- MDL 72222, 161, 661
 Medial prefrontal cortex, 371
 Membrane-protein interactions, 133
 Memory, 37, 145, 287, 433, 509, 877
 Memory deficit, 805
 Metal, 221
 Methamphetamine, 87
 Methylmercury, 555
 Methylscopolamine, 815
 Methylxanthines, 457
 Methysergide, 161, 411
 Mg^{++} -ATPase, 339
 Mice, 63, 233, 281, 451, 457, 519, 627, 805
 Microdialysis, 27, 87
 Microiontophoresis, 217
 Milk, 403
 Mineralocorticosteroid receptor antagonist, 447
 Minipump, 971
 Minocycline, 397
 MK-801, 245, 349, 727
 MK-801 repeated treatment, 683
 Modified open field, 127
 Monoamine oxidase, 321
 Mood, 387, 891
 Morphine, 643, 919
 Morris water maze, 827
 Motor activity, 397
 Motor control, 605
 Motor cortex, 709
 Motor depression, 627
 Motor impairment, 981
 Mouse, 439
 Movement disorders, 321
 μ - and δ -opioid receptors, 497
 Muscarinic receptor(s), 769, 913
 Muscimol, 107
- N-0434, 865
 Na^+, K^+ -ATPase, 339
N-allylnormetazocine, 349
 Naloxone, 119, 329, 381, 763
 Naltrexone, 45
 Naltrexone and quaternary naltrexone, 275
 Naltrindole, 497
 NAN-190, 357, 851
 Nandrolone decanoate, 959
 Narcosis, 547
 Neonatal, 901
 Neonatal rats, 643
 Neurohumor receptors, 755
 Neuroleptic, 181
 Neurotoxicity, 87
 Neurotransmitter, 17
 Nicotine, 51, 199, 217, 387, 657, 689, 735, 891, 913
 Nicotine withdrawal, 51
 Nictitating membrane, 965
 NIK-247, 769
 Nimodipine, 827
 [Nle⁴, D-Phe⁷]- α -MSH, 533
 NMDA, 539
 NMDA complex, 365
 NMDA receptor, 153
 NMDA receptor antagonist, 9
 NMDA-type glutamate receptor, 727
 Nonassociative learning, 965
 Non-NMDA-type glutamate receptor, 727
 Noradrenaline, 381, 475, 519
 Noradrenergic system, 587
 Nordiazepam, 857
 Nordiazepam pharmacokinetics, 857
- Nordiazepam physical dependence, 857
 Norepinephrine, 297, 791, 837
 Novelty-induced hypoalgesia, 381
 Novelty stress, 791
 Novelty-suppressed feeding, 475
 NPY, 71
 Nucleus accumbens, 27, 157, 605, 751, 951
- Ondansetron, 387
 Ontogenetic development, 581
 Open field, 475
 Operant, 403
 Operant behavior, 191, 809, 815
 Opiates, 191
 Opioid(s), 1, 119, 763, 919
 Opioid antagonist, 45
 Opioid agonist, 45
 Opioid drugs, 349
 Opioid receptor blockers, 275
 Opioid system, 365
 Organophosphate, 343, 689
 Organophosphorus compounds, 615
 Oxime, 689
 Oxiracetam, 451
 Oxotremorine, 611, 689, 913
- Pain, 665
 Panic, 673
 Parental behavior, 763
 Parkinsonism, 321
 Paroxetine, 457
 Parvalbumin immunohistochemistry, 877
 Passive avoidance learning, 145
 Pavlovian conditioning, 433, 965
p-chlorophenylalanine, 411
p-CPA, 457
 PD 123319, 623
 Penicillin, 709
 Pentobarbital, 981
 Pentoxifylline, 457
 Pentyleneetetrazol, 581
 Performance, 287, 815
 Perinatal flumazenil (Ro 15-1788), 783
 Perseveration, 735
 Personality, 393
 PGs, 555
 Phencyclidine, 349, 419
 Phenoxybenzamine, 791
 Phenylethylamine, 241
 Pheromone, 281
 Physical stress, 573
 Physostigmine, 343, 451, 689, 805
 Picrotoxin, 975
 Pigeon, 481
 Pilocarpine, 439
 Pimozide, 791, 901
 Pindolol, 357, 851
 Place conditioning, 595
 Plasma renin activity, 623
 Play behavior, 763
 P/NP rats, 657
 Position discrimination, 475
 Postictal inhibition, 113
 Postsynaptic neuron, 457
 Potentiated flight, 673
 Precipitated withdrawal, 497
 Pregnancy, 63
 Prenatal behavior, 843
 Prenatal exposure to morphine, 939
 Prenatal exposure to naloxone, 939
 Preoptic area, 533
 Progumide, 509
- Progressive ratio, 161, 651
 Propofol, 145
 Psychological stress, 527
 Psychomotor stimulants, 191
 Puberty, 281
 Pyridostigmine, 343
- Quinpirole, 487, 843
 Quisqualate/AMPA-type glutamate receptor, 727
 Quisqualic acid, 877
- Rabbit, 965
 Radial arm maze, 735
 Radial arm tunnel maze, 877
 Radial maze, 509
 Rapid tolerance, 981
 Rat(s), 27, 77, 167, 227, 253, 365, 381, 403, 411, 429, 447, 475, 533, 661, 709, 769, 797, 809, 865, 877, 907, 943, 959, 971, 975, 981, 985
 Rat cerebrum and cerebellum, 339
 Rat fetus, 843
 Reactivation, 689
 Rearing, 429, 627, 865
 Receptor autoradiography, 17
 Receptor binding, 45
 Reciprocal hindlimb scratching, 439
 Recognition, 393
 Recovery, 565
 Reinforcement, 127, 245, 735, 891
 Reinforcer, 403
 REM, 797
 Repeated acquisition, 809
 Respiration, 633
 Retention, 419
 Reward, 245, 901
 Reward system, 951
 Rhesus monkey, 633
 Ro 15-4513, 943
 Rolipram, 397
 Roman high- and low-avoidance rats, 783
 Rotarod, 717
 RU 24213, 627
 Runway, 191
- Saliva, 527
 Satiation, 77
 Satiety, 77
 Schedule-controlled behavior, 375
 Schering 23390, 791
 Schizophrenia, 741
 SCH23390, 429, 843
 Scopolamine, 425, 509, 735, 815, 913
 Second messengers, 17
 Sedation, 153
 Seizures, 63, 333, 581, 975
 Selected lines, 501
 Self-administration, 141, 161, 191, 403, 651
 Sensitivity, 307, 709
 Sensitization, 77, 253, 627, 965
 Sensorimotor cortex, 297
 Sensory, 891
 Serotonergic, 777
 Serotonergic system, 411
 Serotonin, 51, 71, 161, 371, 387, 595, 651, 931
 Serotonin₂ antagonists, 797
 Serotonin release, 989
 Sertraline, 51
 Sex behavior, 837

- Sex differences, 313, 763
 Sexual behavior, 913
 Short-term memory, 419
 6-OHDA, 901
 6,7-dinitroquinoxaline-2,3-dione, 727
 SK&F38393, 843
 SK&F83566, 429
 Sleep, 797
 Smoke exposure, 387
 Smoking, 51, 527
 Snakes, 321
 Soman, 343, 615, 689
 Spatial delayed alternation, 565
 Spatial learning, 37, 447, 491, 703, 827
 Spatial reversal, 475
 Spontaneous alternation, 703
 Spontaneous motor activity, 657
 Sprague-Dawley rats, 931
 Squirrel monkeys, 349, 815
 Staircase maze, 587
 Startle, 741
 Stereotypy, 167, 429, 865
 Strain, 805
 Streptozotocin, 491
 Stress, 237, 267, 287, 375, 755, 869
 Stress-induced analgesia, 433
 Striatum, 605
 Subcutaneous, 777
 Substance P (1-7), 439
 Substance P antagonist, 439
 Substance P antiserum, 439
 Substantia nigra, 113, 333
 Substantia nigra pars compacta, 157
 Sucrose solution, 931
 Sufentanil aerosol, 141
 Sulpiride, 843
 Superior colliculus, 333
 Supersensitization, 487
 Suppository, 745
 Sustained-release pellets, 827
 Swiss-Webster mice, 673
 Synergy, 777
 Tacrine, 805
 Taurine, 107, 263
 Telemetry, 689
 Temperature gradient, 501
 Tetrahydroaminoacridine (THA), 769
 Tetramethylammonium, 217
 Theobromine, 457
 Theophylline, 457
 Thermal stimulus, 643
 Thermoregulation, 501, 689
 Thigmotaxis, 429, 463, 865
 3-aminopropanesulphonic acid, 107
 3-PPP, 481
 Thymopentin, 665
 Thyrotropin-releasing hormone, 611
 Tianeptine, 989
 Tiletamine, 1
 Time-related changes, 339
 Tobacco, 387
 Tolerance, 77, 253, 307, 375, 627
 Toxogonin, 689
 Tremors, 611
 Trimethyltin, 555
 Tryptophan, 371
 2-amino-5-phosphonopentanoic acid, 727
 U-50,488H, 77
 Ultrasonic vocalizations, 313
 Unconditioned reflex, 965
 Unilateral labyrinthectomy, 99
 Vestibular compensation, 99
 Vinconate, 17
 Visual cortex, 709
 Voluntary ethanol consumption, 547
 Voluntary ethanol drinking, 127
 Water deprivation, 985
 Water intake, 623
 Water maze, 287
 Weanling rats, 901
 Weight, 51
 Working memory, 411, 805
Xenopus skin mucus, 321
 Xylazine, 1
 Yawning, 487, 601
 Yohimbine, 673, 791, 851
 Zolazepam, 1

PHARMACOLOGY BIOCHEMISTRY & BEHAVIOR

VOLUME 44 1993

AUTHOR INDEX

- Ahlers, S. T., 375
Ally, A., 555
Alpert, C., 397
Amit, Z., 263, 547, 791
Ammassari-Teule, M., 451
Anderson, S. M., 755
Andrews, J. S., 877
Apfelbaum, J. L., 387
Aragon, C. M. G., 263, 547
Araki, T., 17
Arenas, M. C., 233
Aricioglu, F., 939
Arneric, S. P., 37
- Badiani, A., 77
Barbera, N., 665
Barthalmus, G. T., 321
Bassani, J. W. M., 869
Bassani, R. A., 869
Battaglia, M., 451
Bättig, K., 573, 783
Beck, B., 357
Becker, L. A., 925
Behm, F. M., 891
Berge, O.-G., 9
Bernardini, R., 665
Bitrán, M., 981
Blackburn, T. P., 797
Blanchard, D. C., 313, 673
Blanchard, R. J., 313, 673
Blass, E. M., 643
Blick, D. W., 343
Blokland, A., 491
Bocco, G., 403
Bohuon, C., 71
Böo, É., 9
Borowski, T. B., 425
Bosy, T. Z., 133
Botez, M. I., 703
Bowyer, J. F., 87
Boyce, S., 153
Boyeson, M. G., 297
Brahiti, F., 217
Brandão, M. L., 119
Bratton, G. R., 221
Briggs, S. J., 51
Brioni, J. D., 37
Brophy, P. D., 425
Bruhwyler, J., 181
Bruno, J. P., 901
Brus, R., 487
Buckley, M. J., 37
Buist, R., 555
- Cai, B., 519
Cantarella, G., 665
Capacio, B. R., 615
Carr, D. B., 763
- Castellano, C., 451
Chaouloff, F., 989
Chen, C.-J., 281
Chiarenza, A., 665
Chleide, E., 181
Chotro, M. G., 403
Chow, S. Y.-M., 985
Christopher, N. C., 51
Clark, D., 167
Clement, J. G., 689
Cook, G., 153
Cook, L. A., 615
Coscina, D. V., 777
Cottrell, G. A., 157, 429
Cox, B., 797
Crabbe, J. C., 501
Cramer, C. P., 643
Crawshaw, L. I., 501
Cuadra, G. R., 237
Curzon, P., 37
- Dakis, M., 419
Dall'Olio, R., 683
Daly, J. W., 199
Darlington, C. L., 99
Davies, A. M., 595
Dawes, P., 381
De Brabander, J. M., 565
De Bruin, J. P. C., 565
Decker, M. W., 37
DeHaven-Hudkins, D. L., 45
Demissie, S., 275
de Rooy, E. C. H., 777
De Souza, E. B., 755
Djali, S., 357
Dominguez, H. D., 403
Drago, F., 665
Driscoll, P., 783
Duran, E., 307
- Echevarria, E., 797
Edling-Owens, J., 745
Ellinwood, Jr., E. H., 253, 971
Elsohly, M. A., 745
Engelman, K., 745
Ergene, E., 951
Escorihuela, R. M., 783
Esseling, K., 709
Ettenberg, A., 191
- Fadden, C., 837
Fanelli, R. J., 827
Fanselow, M. S., 643
Fenton, L. H., 357
Fernández-Teruel, A., 783
Fisher, H., 931
Flood, J. F., 577
Fregley, M. J., 623
- Fuchs, I., 397
Fukuda, T., 611
Furmidge, L., 167
- Gandolfi, O., 683
Garity, D., 901
Geist, T. D., 191
Geyer, M. A., 741
Ghanta, V. K., 275
Ghi, P., 587
Giacobini, E., 727
Gilchrist, D. P. D., 99
Glasky, A. J., 805
Goeders, N. E., 471
Gordon, T. L., 657
Gosnell, B. A., 919
Gough, B., 87
Grade, C. M., 297
Graham, A., 763
Grecksch, G., 227
Grover, C. A., 221
Grupp, L. A., 985
Guerin, G. F., 471
Gupta, U., 393
- Hails, R., 837
Han, P. C., 63
Hardin, L. K., 321
Harro, J., 509
Harvey, J. A., 965
Heaton, J. P. W., 601
Helmstetter, F. J., 433
Hennessy, M. B., 925
Herberg, L. J., 113
Himmi, T., 217
Hiramoto, N. S., 275
Hiramoto, R. N., 275
Ho, I. K., 497
Hofer, I., 573
Holson, R. R., 87
Holtzman, S. G., 349
Horita, A., 365
Horn, E., 709
Hoskins, B., 497
Houbeau, G., 181
Hsueh, C.-M., 275
- Inoue, T., 371
Ishida, Y., 17
Iurato, M. P., 665
Iverson, S. D., 153
Iwata, S.-I., 611
- Jacobson, K. A., 199
Jacquot, C., 71
Jaffe, J. H., 141
Jäkälä, P., 411
- Järbe, T. U. C., 481
Jaw, S. P., 497
Jodogne, C., 627
Jolles, J., 491
Joseph, M., 447
Joyal, C. C., 539, 703
Joyner, C., 253, 971
- Kaddis, F. G., 245
Kafetzopoulos, E., 751
Kalant, H., 981
Kameyama, T., 907
Kanai, Y., 17
Kant, G. J., 287, 755
Kato, H., 17
Kellogg, C. K., 267
Kerenyi, S. Z., 343
Kesner, R. P., 419
Kimura, K., 27
King, G. R., 253, 971
Kinsley, C. H., 763
Kirschbaum, C., 527
Kisara, K., 439
Kitatani, T., 457
Klimek, V., 821
Kling, A., 805
Knickerbocker, D., 533
Koechling, U. M., 791
Kofman, O., 397
Kogure, K., 17
Kokkinidis, L., 425
Komer, K. M., 45
Konstandi, M., 751
Kontopoulos, A. N., 339
Koob, G. F., 943
Kopman, J. A., 249
Korpi, E. R., 127
Kostrzewa, R. M., 487
Koyama, T., 371
Koyuncuoglu, H., 939
Krahn, D. D., 919
Krechman, J., 943
Krobert, K. A., 297
Kubová, H., 581
- Lacosta, S., 161, 651
Lalonde, R., 539, 703
Lang, C. M., 1
Langkrär, J., 527
Lapin, I. P., 241
Larach, D. R., 1
Layer, R. T., 245
Lee, T. H., 253, 971
Lempereur, L., 665
Levin, E. D., 51, 891
Lichter, J. L., 387
Liljequist, R., 107
Lipe, G. W., 87

- Loh, E. A., 735
 Lu, M.-R., 931

 Mackenzie-Taylor, D. R., 717
 Magee, L. K., 673
 Mahan, K., 605
 Manome, Y., 439
 Mareš, P., 581, 975
 Marten, P., 877
 Martin, C., 167
 Martin, W. R., 857
 Matsumoto, K., 519
 Matsunaga, Y., 439
 Matsuoka, Y., 727
 Mattes, R. D., 745
 Matthies, H., 227
 Mavunkel, B. J., 45
 McGregor, A., 651
 McMonagle-Strucko, K., 827
 McNulty, M. A., 471
 Meehan, S. M., 657
 Melchior, C. L., 805
 Mele, P. C., 809
 Melton, P. M., 249
 Menard, J., 463
 Mercier, M., 181
 Meyer, M. E., 157, 329, 429, 865, 959
 Mičlaniková, D., 975
 Miller, S. A., 343
 Mills, P., 555
 Minkin, D. M., 959
 Mintz, M., 113
 Moerschbaeher, J. M., 815
 Molina, J. C., 403
 Molina, V. A., 237
 Molinengo, L., 587
 Moody, C. A., 843
 Mori, E., 907
 Morley, J. E., 577
 Morley, P. M. K., 577
 Morse, W. H., 633
 Motta, V., 119
 Murphy, M. R., 343

 Naritoku, D., 727
 Nässtrom, J., 9
 Nation, J. R., 221
 Newport, G. D., 87
 Nikodijević, O., 199
 Nikulina, E. M., 821
 Nomikos, G. G., 27
 Nomoto, M., 611

 O'Connor, C. S., 501
 Ohno, M., 769
 Ohta, H., 519
 Oitzl, M. S., 447
 Orelan, L., 509
 Orosco, M., 71
 Orsetti, M., 587
 Orsini, J. C., 217

 Pages, N., 71
 Päiväranta, P., 127
 Pakarinen, E. D., 815
 Palazzesi, S., 451
 Pang, R., 145
 Parker, L. A., 595
 Parra, A., 233
 Pastel, R. H., 797
 Pastorello, B., 587
 Peris, J., 333
 Perrin, J., 217
 Peterson, J. A., 45
 Petry, N., 167
 Plech, A., 487
 Pleger, L., 267
 Potter, T. J., 429, 865

 Quartermaine, D., 145

 Rabin, R. A., 851
 Raible, L. H., 533
 Rakonczay, Z., 727
 Rassnick, S., 943
 Rathouská, J., 581
 Rech, R. H., 717
 Retana-Marquez, S., 913
 Reuhl, K., 555
 Reyes, E., 307
 Riekkinen, Jr., P., 411
 Riekkinen, Sr., P., 411
 Riley, A. L., 249
 Ritzmann, R. F., 805
 Roberts, D. C. S., 161, 651, 735
 Robinson, M. B., 357
 Robinson, S. R., 843
 Rochford, J., 381
 Rodgers, R. J., 673
 Rodriguez-Zafra, M., 267
 Rogers, C. F., 275
 Rogers, S., 605
 Rokyta, R., 975
 Romano, A. G., 965
 Rose, I. C., 113

 Rose, J. E., 51, 891
 Rosman, E., 145
 Rouch, C., 71
 Rowland, N. E., 623
 Royan, C., 463
 Rupniak, N. M. J., 153
 Rührich, H.-L., 227
 Rykaczewska, M., 487
 Rzeszotarski, W. J., 45

 Sakurada, S., 439
 Sakurada, T., 439
 Salamone, J. D., 605
 Salander, M. K., 375
 Salazar, E. D., 913
 Sansone, M., 451
 Scapagnini, U., 665
 Schechter, M. D., 657, 661
 Scherer, P. J., 297
 Schoener, E. P., 951
 Scott, J. D., 333
 Sharpe, L. G., 141
 Shaw, L. M., 745
 Shibuya, T., 457
 Shih, T.-M., 615
 Shuto, K., 17
 Sidhu, K. S., 901
 Simón, V. M., 233
 Sirvio, J., 411
 Slikker, Jr., W., 87
 Sloan, J. W., 857
 Smith, A. M., 735
 Smith, P. F., 99
 Smolen, A., 63
 Smolen, T. N., 63
 Smotherman, W. P., 843
 Soong, S.-J., 275
 Spear, L. P., 843
 Spear, N. E., 403
 Spriujt, B. M., 447
 Stahlberg, M., 9
 Steckler, T., 877
 Steger, R. W., 837
 Stellar, J. R., 901
 Stewart, J., 77, 381
 Strasburger, C. J., 527
 Sugimachi, K., 769
 Svensson, T. H., 27
 Swerdlow, N. R., 741
 Switzer, S. H., 307

 Tan-No, K., 439
 Tanila, H., 475

 Taukulis, H. K., 313, 673
 Taylor, M. K., 267
 Teeple, E. S., 633
 Thompson, D., 321
 Tirelli, E., 627
 Toboña, A., 783
 Tong, Z.-Y., 167
 Tortella, F. C., 797
 Treit, D., 463
 Tsakiris, S., 339
 Turndorf, H., 145
 Turner, J. D., 877
 Tye, S., 153

 Ueki, S., 769
 Ukai, M., 907
 Ushijima, I., 365

 Vandenberg, G., 281
 Van Eden, C. G., 565
 van Embden, S., 397
 van Haaren, F., 959
 Van Hartesveldt, C., 157, 429
 Varrin, S. J., 601
 Velazquez-Moctezuma, J., 913
 Velišek, L., 975
 Velišková, J., 975
 Vorlíček, J., 581

 Waegeneer, N., 181
 Wagner, G. C., 931
 Wala, E. P., 857
 Wallace, L. J., 245
 Waltrip, L. A., 133
 Watanabe, H., 519
 Watanabe, Y., 457
 Weber, R., 709
 Wehner, J. M., 133
 Weinhold, L. L., 141
 Wellman, J. C., 763
 Wettstein, J. G., 633
 Wilson, R. P., 1
 Winsauer, P. J., 809
 Winter, J. C., 851

 Yamamoto, T., 769
 Yamashita, I., 371
 Yao, O., 71
 Yudko, E. B., 313

 Zacny, J. P., 387
 Zagon, I. S., 1
 Zaragoza, J. G., 387